NCT03972462View on ClinicalTrials.gov

NPC-12G Gel 0.2% Sirolimus PK Bridging Study

PHASE1CompletedINTERVENTIONAL

Enrollment

12

Participants

Timeline

Start Date

May 31, 2019

Primary Completion Date

June 17, 2019

Study Completion Date

June 17, 2019

Conditions

Bioavailability Study

Interventions

DRUG

NPC-12G Gel 0.2%

Period 1

DRUG

Rapamune® 2 mg tablet

Period 2

Trial Locations (1)

33136

InVentiv Health Clinical Research Services LLC, Miami

Sponsors

Lead Sponsor

All Listed Sponsors

lead

Nobelpharma

INDUSTRY

NCT03972462 - NPC-12G Gel 0.2% Sirolimus PK Bridging Study | Biotech Hunter | Biotech Hunter